Source:

Press Release

July 22, 2021
1 min read
Save

Dexycu may receive extension of pass-through payment status

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

EyePoint Pharmaceuticals anticipates a 9-month extension to Dexycu’s pass-through payment status, according to a press release.

The current pass-through payment status for Dexycu (dexamethasone intraocular suspension 9%) would expire on March 31, 2022, without an extension, the release said.

“We are extremely pleased that the CMS has indicated it intends to provide additional pass-through time, subject to public comment, allowing for another 9 months of pass-through status for important innovative products such as Dexycu,” Nancy Lurker, CEO of EyePoint Pharmaceuticals, said in the release.

CMS released the 2022 draft Hospital Outpatient Prospective Payment System rule on July 19, with a final rule expected to come in November, the release said.